The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

Discover the first FDA-approved weight loss medication for obstructive sleep apnea, Zepbound by Eli Lilly. Learn how it can reduce apnea events and CPAP market.

“This is the first pharmacologic therapy that can treat obstructive sleep apnea in this way,” says Dan Skovronsky, chief scientific officer at Eli Lilly. Read More: Is Intermittent Fasting ...

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

Obstructive sleep apnea – disruptive snoring – is linked to conditions such as high blood pressure and heart disease and other hazards to your health. Learn more from WebMD. Pillows that put ...

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea syndrome (OSAS) per se, although only some patients ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

The FDA has expanded the approval of Eli Lillys obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication approved ...